TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 39.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,447 shares of the biopharmaceutical company's stock after selling 8,932 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in TG Therapeutics were worth $405,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Blue Trust Inc. lifted its stake in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after buying an additional 1,737 shares during the period. Synergy Asset Management LLC acquired a new position in shares of TG Therapeutics during the 4th quarter valued at about $75,000. Finally, GAMMA Investing LLC lifted its holdings in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 2,171 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of research firms recently issued reports on TGTX. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.67.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.50% of the company's stock.

TG Therapeutics Stock Down 0.8 %

Shares of NASDAQ TGTX traded down $0.34 on Friday, hitting $39.86. The company had a trading volume of 1,642,962 shares, compared to its average volume of 3,069,404. The firm has a market capitalization of $6.26 billion, a P/E ratio of -398.56 and a beta of 2.30. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The business has a 50 day moving average of $34.37 and a two-hundred day moving average of $30.29. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.